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Abstract 
 
Objective. There has been continuous debate regarding the applicability of various composite 
measures for the assessment of disease activity in rheumatoid arthritis (RA). In order to 
further dissect this issue, we numerically and graphically modeled DAS28, SDAI and CDAI 
by 3-dimensional plotting. We wished to graphically visualize the relative contribution of 
various elements in the three activity indices to each other.  
Methods. We calculated DAS28 (3-variable), SDAI and CDAI by the standard equations. We 
plotted 3-dimensional (3D) “carpets” showing all combinations of the corresponding variables 
yielding to DAS28=5.1, DAS28=3.2, DAS28=2.6, SDAI=26, SDAI=11 and SDAI=3.3. We 
also plotted the 3D carpet for CDAI.  
Results: In patients with high or moderate disease activity, erythrocyte sedimentation rate 
(ESR) or C-reactive protein (CRP) were not major confounding factors when calculating 
DAS28 and SDAI, respectively. In contrast, ESR and CRP highly overshadowed changes in 
joint counts and global assessments in patients with low disease activity (LDA) or in those in 
remission. No reliable assessment of LDA can be performed in cases where ESR>54 mm/h or 
CRP>20 mg/dl. Similarly, remission cannot be determined if ESR>19 mm/h or CRP>5 mg/dl. 
As CDAI does not include acute phase reactants, CDAI may be a useful tool even in states of 
remission or LDA.    
Conclusions: Our results suggest that acute phase reactnats are indeed major confounding 
factors and should be omitted when assessing RA disease activity, at least in special cases. 
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Introduction 
 Rheumatoid arthritis (RA) is a progressive inflammatory rheumatic disease, which 
may lead to joint destruction and disability. Thus, early diagnosis, close follow-up and early, 
effective treatment are imperative in order to prevent structural damage and functional 
impairment (1, 2). Various instruments have been developed in order to accurately determine 
disease activity of RA at any given timepoint during the disease course (2). Among disease 
activity indices, the 28-joint disease activity scale (DAS28) has long been used in the daily 
practice, as well as in clinical trials. The 3-variable DAS28 (DAS28-V3) includes erythrocyte 
sedimentation rate (ESR), swollen (SJC) and tender joint counts (TJC) determined in 28 
designated joints, while the 4-variable version (DAS28-V4) also includes patient-determined 
global health (GH) assessed on a 100-mm visual analogue scale (VAS) (2-4). However, the 
somewhat complicated formula requires the use of special calculators or computer softwares 
(Table 1). Therefore a simplified disease activity index (SDAI) has later been developed by 
simply adding five variables including SJC, TJC in 28 joints, C reactive protein level (CRP, 
mg/dL), as well as patient- (PGA) and evaluator-determined global disease activity (EGA) 
assessed by 10-cm VAS (5-7). Some further studies suggested that the determination of acute 
phase reactants (APR), such as ESR or CRP add little to the other four parameters when 
assessing SDAI (8). Therefore an even more simple clinical disease activity index (CDAI) has 
been introduced by omitting CRP and just adding the other four variables, SJC, TJC, PGA 
and EGA (5, 6, 9). The elements of these composite indices and the calculation formulas are 
included in Table 1. 
   It has become clear from routine clinical practice that the “APR issue” may have 
another important aspect. Apart from not giving extra value during the determination of 
disease activity (8), ESR and CRP may even overshadow the other clinical parameters. 
Indeed, APRs reflect systemic inflammation and, in most patients, reflect disease activity. 
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However, we often see patients with LDA of RA, yet highly elevated ESR or CRP levels due 
to other confounding factors, such as infections, paraproteins or simply high immunoglobulin 
or total protein levels. On the other hand, some patients may have highly destructive RA 
despite “low-grade” inflammation. In such conditions, very low or very high APR levels may 
override the influence of other clinical variables when determining DAS28 or SDAI. As very 
recently published by Smolen and Aletaha (10), the determination of response to biologics 
may be highly influenced by APRs as much better reponse to tocilizumab was observed using 
DAS28 in comparison to CDAI. 
 In order to further dissect this issue, we numerically and graphically modeled DAS28, 
SDAI and CDAI by 3-dimensional plotting. Our aim was to compare and graphically 
visualize the relative contribution of various elements in the three activity indices to each 
other. Our results suggest that APRs are indeed major confounding factors and should be 
omitted when assessing RA disease activity, at least in special cases. 
  
Methods 
  
DAS28-V3 graphs 
 
We used the 3-variable version of DAS28. DAS28-V3 was calculated by using the 
standard equation of DAS28 = (0.56 x √‾ TJC + 0.28 x √‾ SJC + 0.7 x ln ESR) x 1.08 + 0.16. 
According to the definition of high, low disease activity and remission (Table 1), DAS28 = 
5.1, 3.2 and 2.6, respectively, were calculated using all possible TJC (0-28), SJC (0-28) and 
ESR (0-100 mm/h) values. Then, three-dimensional (3D) graphs were plotted with TJC, ESR 
and SJC on the X, Y and Z axes, respectively, expressing DAS28 values of 5.1 (Figure 
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1a,B,C), 3.2 (Figure 2A,B,C) and 2.6 (Figure 3A,B,C). 3D “carpets” are presented as 
snapshots taken from different views.  
 
SDAI graphs 
 
SDAI was calculated by the standard equation of SDAI = TJC + SJC + PGA + EGA + 
CRP, assessing 28-jount counts (Table 1). As five variables cannot be plotted in 3D graphs, 
TJC and SJC were added yielding to a composite joint score (TJC+SJC: 0-56), PGA and EGA 
were also added yielding to a composite assessment score (PGA+EGA: 0-20) and these two 
composite scores were plotted against CRP. Now we ended up with only 3 variables. As the 
SDAI limits between high/moderate, moderate/LDA and LDA/remission are 26, 11 and 3.3, 
respectively (Table 1), we plotted three 3D graphs expressing SDAI values of 26 (Figure 4), 
11 (Figure 5) and 3.3 (Figure 6). In these “carpets”, TJC+SJC, CRP and PGA+EGA were 
plotted on the X, Y and Z axes, respectively.  
 
CDAI graphs 
 
CDAI was calculated by the standard formula of CDAI = TJC + SJC + PGA + EGA 
by assessing 28 joints (Table 1). As 4 variables cannot be plotted in 3D graphs and we also 
wished to compare SDAI and CDAI graphs, we, similarly to what was performed in the case 
of SDAI, we again formed two composite indices by adding TJC+SJC and also PGA+EGA. 
This yielded to only two variables so in this situation TJC+SJC and PGA+EGA were plotted 
on X and Z axis, and all CDAI values could be visualized in on the Y axis of 3D carpets 
(Figure 7A,B).  
 
Page 5 of 29 Manuscript Submitted to Clinical Rheumatology for Review
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 6
Results  
 
The DAS28 carpets 
 
 In Figures 1, 2 and 3 carpets of DAS28=5.1, 3.2 and 2.6 are visualized as snapshots 
taken from three different views (A,B,C), respectively. The DAS28=5.1 carpet (Figure 1A-C) 
reflects all possibilities, how high disease activity can be presented. When looking at some 
examples, on one hand, taken the maximum SJC and TJC values of 28 each, ESR = 1.2 mm/h 
indicating that DAS28=5.1 can be reached if ESR is above 1 mm/h. In addition, patients with 
0 or 1 tender and/or swollen joints would require ESR > 200 mm/h to reach DAS28=5.1, 
which is defitely not realistic. Thus, in the case of DAS28=5.1, ESR is not a major 
confounding factor.  
 When the carpet of DAS28=3.2 is plotted (Figure 2A-C), it is clear from the examples 
that zero TJC and SJC correspond with ESR=54 mm/h. Thus, patients with ESR > 54 mm/h 
may never reach LDA. As some patients may exert higher ESR despite of no or very few 
tender and swollen joints, ESR may be a confounding factor when calculating DAS28 and 
may override the weight of the other two variables. 
 Similarly, when the carpet of DAS28=2.6 is visualized (Figure 3A-C), zero TJC and 
SJC correspond with ESR=19 mm/h. Thus, RA patients with ESR>19 mm/h would never 
reach the state of remission.  
 
The SDAI carpets 
 
    In Figures 4, 5 and 6, carpets of SDAI=26, SDAI=11 and SDAI=3.3 are visualized as 
snapshots, respectively. The SDAI=26 carpet (Figure 4) reflects all possibilities, how high 
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disease activity can be reached. If SJC+TJC or PGA+EGA sums are below 26, CRP is 
positive. In the case of cutoff between moderate and low disease activity (SDAI=11), most of 
the carpet is “on the floor”, only TJC+SJC or PGA+EGA sums below 11 would yield positive 
CRP values (Figure 5). As for remission (SDAI=3.3), CRP must be 3.3 mg/dl or lower that 
yields to an almost flat graph. Both the TJC+SJC and the PGA+EGA sums must be <3, 
otherwise CRP would yield negative value (Figure 6). Thus, in the case of relatively high 
joint and/or assessment scores (>26), high disease activity can easily be reached, irrespective 
of CRP (Figure 4). In contrast, when the carpets of SDAI=11 and SDAI=3.3 are plotted 
(Figures 5 and 6), almost the whole carpet is “on the floor”. In these cases, CRP cannot be 
more than 11 mg/dl or 3.3 mg/dl, respectively, otherwise CRP would be a confounding factor 
when calculating SDAI and may override the weight of the other four variables. In other 
words, patiernts with CRP>11 mg/dl or with CRP>3.3 mg/dl could never show SDAI-
determined LDA or remission, respectively (Figure 5 and 6). 
  
The CDAI carpets 
 
 In Figure 7 (A and B), CDAI values are plotted on the Y axis against composite joint 
(X axis) and assessment scores (Z axis) formed similarly to SDAI visualization. CDAI carpets 
are visualized as snapshots taken from two different views (A,B). CDAI does not include 
CRP or ESR and is a simple sum of SJC+TJC+EGA+PGA. Thus, the calculation of CDAI is 
solely based on joint scores, as well as patient’s and doctor’s general assessments. As seen in 
Figure 7, there is no “carpet-on-floor” area indicating that CDAI is closely and linearly related 
with either joint counts or general assessments. Therefore, moderate disease activity 
(CDAI≤22), low disease activity (CDAI≤10) or remission (CDAI≤2.8) can be calculated upon 
any combination of the four variables, independent of any other confounding factors. Indeed, 
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a mean variable value of 5.5, 2.5 and 0.7 or less are required to reach moderate, low disease 
activity or remission, respectively.   
   
Discussion 
 
 There has been continuous debate regarding the comparison and practical use of three 
different disease activity composite indices, DAS28, SDAI and CDAI in RA. In 2005, 
Aletaha et al (8) proposed that APRs added little to composite indices. This led to the 
development of CDAI, an index not containing ESR or CRP (6, 11, 12).  
 As most published papers presented calculations, we wished to visualize the 
distribution of various components in the three composite indices by drawing 3-dimensional 
“carpets” and by also presenting some examples in tables. 
 Our data confirm that while APRs may be useful when calculating DAS28 or SDAI in 
RA patients with high or moderate disease activity, ESR and/or CRP may be confounders of 
these calculations in patients with low disease activity or in those in remission. When using 
DAS28, ESR values >54 mm/h and >19 mm/h or, similarly, when calculating SDAI, CRP 
values >11 mg/dl and >3.3 mg/dl make the respective determination of LDA and remission 
impossible. In contrast, CDAI carpets indicate very good correlations of RAQ disease activity 
with joint scores, as well as patient- and doctor-determined measures without the confounding 
effects of APRs.  
 Some groups have also suggested that composite indices, such as DAS28 or SDAI 
may exert problems when used in remission or in LDA states (12-15). It is imperative to use 
proper tools to assess remission and LDA, as nowadays, according to the recent EULAR and 
treat-to-target recommendations, standard care, as well as clinical trials should target these 
disease states (13, 16-19). Furthermore, remission has also been associated with radiographic 
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progression, especially in patients with residual joint swelling (20). Interestingly, as among 
biologics tocilizumab may have outstanding suppressive effects on APR production, APR-
containing composite measures may be very sensitive tools in this special setting (15).    
 Very recently, Bentley et al (11) developed a modified version of DAS28 (mDAS28) 
that also lacks APRs. Modified DAS28 showed substantial agreement with DAS28, SDAI 
amd CDAI. 
 In conclusion, our visualization of RA disease-activity “carpets” confirm that ESR 
and/or CRP may be significant confounding factors when assessing patients in remission or 
those with LDA. 
  
Figure legends 
 
Figure 1. Variability of three components (erythrocyte sedimentation rate [ESR], tender 
[TJC] and swollen jount counts [SJC]) leading to DAS28=5.1 (borderline between high and 
moderate disease activity) shown as a 3-dimensional “carpet” from three viewpoints 
(1A,1B,1C).   
 
Figure 2. Variability of three components (erythrocyte sedimentation rate [ESR], tender 
[TJC] and swollen jount counts [SJC]) leading to DAS28=3.2 (borderline between moderate 
and low disease activity) shown as a 3-dimensional “carpet” from three viewpoints 
(2A,2B,2C).   
 
Figure 3. Variability of three components (erythrocyte sedimentation rate [ESR], tender 
[TJC] and swollen jount counts [SJC]) leading to DAS28=2.6 (borderline between low 
disease activity and remission) shown as a 3-dimensional “carpet” from three viewpoints 
(3A,3B,3C).   
 
Figure 4. Variability of three components (C reactive protein [CRP], tender [TJC] + swollen 
jount counts [SJC], patient’s [PGA] + doctor’s global assessment [EGA]) leading to SDAI=26 
(borderline between high and moderate disease activity) shown as a 3-dimensional “carpet”.   
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Figure 5. Variability of three components (C reactive protein [CRP], tender [TJC] + swollen 
jount counts [SJC], patient’s [PGA] + doctor’s global assessment [EGA]) leading to SDAI=11 
(borderline between moderate and low disease activity) shown as a 3-dimensional “carpet”.   
 
Figure 6. Variability of three components (C reactive protein [CRP], tender [TJC] + swollen 
jount counts [SJC], patient’s [PGA] + doctor’s global assessment [EGA]) leading to 
SDAI=3.3 (borderline between low disease activity and remission) shown as a 3-dimensional 
“carpet”.   
   
Figure 7. Variability of tender [TJC] + swollen jount counts [SJC], patient’s [PGA] + 
doctor’s global assessment [EGA] and CDAI shown as a 3-dimensional “carpet” from two 
viewpoints (7A,7B).   
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Table 1 Calculation and interpretation of DAS28-V3, SDAI and CDAI 
 
 
 Formula High disease 
activity 
Moderate 
disease activity 
Low 
disease 
activity 
Remission 
DAS28-
V3 
(0.56 x √‾ TJC + 0.28 x √‾ SJC + 
0.7 x ln ESR) x 1.08 + 0.16 
>5.1 ≤5.1 ≤3.2 ≤2.6 
SDAI(28) TJC + SJC + PGA + EGA + CRP >26 ≤26 ≤11 ≤3.3 
CDAI(28) TJC + SJC + PGA + EGA >22 ≤22 ≤10 ≤2.8 
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